BS_9XVACXP0
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- age_years
- 0.192
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.507
- G2M_CHECKPOINT+0.477
- MYC_TARGETS_V2+0.474
- CHOLESTEROL_HOMEOSTASIS+0.443
- E2F_TARGETS+0.412
- UNFOLDED_PROTEIN_RESPONSE+0.409
- MTORC1_SIGNALING+0.390
- TGF_BETA_SIGNALING+0.349
- MITOTIC_SPINDLE+0.332
- DNA_REPAIR+0.278
Top 10 suppressed
- BILE_ACID_METABOLISM-0.301
- MYOGENESIS-0.239
- INTERFERON_GAMMA_RESPONSE-0.233
- KRAS_SIGNALING_DN-0.226
- INTERFERON_ALPHA_RESPONSE-0.207
- ALLOGRAFT_REJECTION-0.158
- ADIPOGENESIS-0.142
- PEROXISOME-0.120
- COMPLEMENT-0.107
- HEDGEHOG_SIGNALING-0.106
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.860 |
| 2 | TCGA-85-8351-01A-11R-2296-07 | — | cohortSQ1 | 0.854 |
| 3 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.848 |
| 4 | ERR2598051 | fetal | fetal | 0.844 |
| 5 | 5ca9ac39-e175-4890-ba6e-9ff4709d3f37 | — | — | 0.839 |
| 6 | TCGA-66-2753-01A-01R-0980-07 | — | cohortSQ1 | 0.836 |
| 7 | A3153235-3128-40AC-9371-AFA1F61E3E59 | — | — | 0.834 |
| 8 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.833 |
| 9 | SRR934935 | — | — | 0.833 |
| 10 | SRR4195653 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.507 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.477 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.474 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.443 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.412 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.409 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.349 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.332 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.278 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.252 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.237 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.212 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.156 | Inavolisib | — uncovered |
| HYPOXIA | 0.146 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.137 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.136 | Inavolisib | — uncovered |
| COAGULATION | 0.124 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.124 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.117 | Idelalisib | — uncovered |